tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Avidity Biosciences price target raised to $62 from $59 at Barclays

Barclays raised the firm’s price target on Avidity Biosciences (RNA) to $62 from $59 and keeps an Overweight rating on the shares. The firm views the company’s Q2 report as largely incremental.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1